1. Home
  2. SLNH vs ACOG Comparison

SLNH vs ACOG Comparison

Compare SLNH & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soluna Holdings Inc.

SLNH

Soluna Holdings Inc.

HOLD

Current Price

$1.73

Market Cap

127.9M

Sector

Technology

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$5.88

Market Cap

110.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLNH
ACOG
Founded
1961
2000
Country
United States
Canada
Employees
52
57
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
127.9M
110.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SLNH
ACOG
Price
$1.73
$5.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$5.00
$16.00
AVG Volume (30 Days)
26.7M
29.6K
Earning Date
05-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$55.83
$139.22
Revenue Next Year
N/A
$134.48
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.42
$4.50
52 Week High
$5.14
$10.88

Technical Indicators

Market Signals
Indicator
SLNH
ACOG
Relative Strength Index (RSI) 52.58 49.17
Support Level $1.59 $5.73
Resistance Level $1.74 $6.34
Average True Range (ATR) 0.26 0.38
MACD -0.04 0.01
Stochastic Oscillator 26.90 68.48

Price Performance

Historical Comparison
SLNH
ACOG

About SLNH Soluna Holdings Inc.

Soluna Holdings Inc is a U.S.-based company engaged in the development and operation of data centers powered by renewable energy. The company utilizes excess or curtailed energy from renewable sources to support high-performance computing applications, including cryptocurrency mining, artificial intelligence, and machine learning. Its business model focuses on converting underutilized renewable energy into computing resources through co-located data center infrastructure.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: